

**In the Claims**

1.-16. (Canceled)

17. **(Currently Amended)** A method of inhibiting angiogenesis in a diseased eye of a subject, comprising, administering intraocularly **a recombinant adeno-associated virus (rAAV) a-retroviral** gene delivery vector which directs the expression of an anti angiogenic factor, such that administration of said vector inhibits neovascularization of the diseased eye.

18. **(Previously Presented)** The method according to claim 17 wherein said anti-angiogenic factor is soluble Flt-1, PEDF, soluble Tie-2 receptor, or a single chain anti-VEGF antibody.

19. **(Previously Presented)** The method according to claim 17 wherein said diseased eye is in a subject having diabetic retinopathy, wet AMD or retinopathy of prematurity.

20. – 44. (Canceled)